PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols

par Natalya V. Maluchenko, Alexey V. Feofanov, Vasily M. Studitsky
Publié 2021

AIF, PARP-1 and MicroRNA-9 Expression in Cerebral Ischemia Associated to Alcoholism Experimental Model

par Abrahão,Dayana Pousa Siqueira, Lizarte Neto,Fermino Sanches, Rodrigues,Andressa Romualdo, Cirino,Múcio Luiz de Assis, Silva,Jairo Pinheiro da, Sarraipo,Vagner Schiavoni, Carvalho,Camila Albuquerque Melo de, Tazima,Maria de Fátima Galli Sorita, Carlotti-Jr.,Carlos Gilberto, Colli,Benedicto Oscar, Tirapelli,Luís Fernando, Tirapelli,Daniela Pretti da Cunha
Publié 2020

Cáncer de mama triple negativo: terapias sistémicas actuales y experiencia local

par Luque S.,Glomaryeth, Walbaum G.,Benjamin, Camus A.,Mauricio, Domínguez C.,Francisco, Merino L.,Tomas, Acevedo C.,Francisco, Sánchez R.,César
Publié 2021

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice

par Liu F, Gong L, Qin W, Cui C, Chen L, Zhang M
Publié 2020

The Making and Breaking of Serine-ADP-Ribosylation in the DNA Damage Response

par Kira Schützenhofer, Johannes Gregor Matthias Rack, Ivan Ahel
Publié 2021

Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment

par Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S
Publié 2018

Modulatory effect of Persea Americana oil against diethylnitrosamine-induced hepatotoxicity in rats: a proposed mechanism

par Omayma A. R. Abozaid, Lobna M. Anees, Gehan R. Abdel-Hamed
Publié 2021

Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer

par Lili Gao, Rui Chen, Ting Li, Lujin Li, Qingshan Zheng
Publié 2021

PARP Inhibitors and Haematological Malignancies—Friend or Foe?

par Kathryn A. Skelding, Lisa F. Lincz
Publié 2021

Temporal and Site-Specific ADP-Ribosylation Dynamics upon Different Genotoxic Stresses

par Sara C. Buch-Larsen, Alexandra K. L. F. S. Rebak, Ivo A. Hendriks, Michael L. Nielsen
Publié 2021

Optimizing the Schedule of PARP Inhibitors in Combination with ¹⁷⁷Lu-DOTATATE: A Dosimetry Rationale

par Andreas Hallqvist, Johanna Svensson, Linn Hagmarker, Ida Marin, Tobias Rydén, Jean-Mathieu Beauregard, Peter Bernhardt
Publié 2021

<named-content content-type="genus-species">Trypanosoma cruzi</named-content> Induces the PARP1/AP-1 Pathway for Upregulation of Metalloproteinases and Transforming Growth Factor β...

par Subhadip Choudhuri, Nisha Jain Garg
Publié 2020

Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer

par Rongjia Su, Yuan Liu, Xiaomei Wu, Jiangdong Xiang, Xiaowei Xi
Publié 2021

PARP-1 and SIRT-1 are Interacted in Diabetic Nephropathy by Activating AMPK/PGC-1&alpha; Signaling Pathway

par Zhu H, Fang Z, Chen J, Yang Y, Gan J, Luo L, Zhan X
Publié 2021

Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?

par Paul DiSilvestro, Nicoletta Colombo, Philipp Harter, Antonio González-Martín, Isabelle Ray-Coquard, Robert L. Coleman
Publié 2021

Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells

par Luca X. Zampieri, Martina Sboarina, Andrea Cacace, Debora Grasso, Léopold Thabault, Loïc Hamelin, Thibaut Vazeille, Elodie Dumon, Rodrigue Rossignol, Raphaël Frédérick, Etienne Sonveaux, Florence Lefranc, Pierre Sonveaux
Publié 2021

MVP Expression Facilitates Tumor Cell Proliferation and Migration Supporting the Metastasis of Colorectal Cancer Cells

par Paulina Pietras, Marta Leśniczak-Staszak, Aldona Kasprzak, Małgorzata Andrzejewska, Karol Jopek, Mateusz Sowiński, Marcin Rucinski, Shawn M. Lyons, Pavel Ivanov, Witold Szaflarski
Publié 2021

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

par Hongmei Wang, Meng Wu, Haonan Liu, Hang Zhou, Yang Zhao, Yifan Geng, Bo Jiang, Kai Zhang, Bo Zhang, Zhengxiang Han, Xiuping Du
Publié 2021

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?

par Amelia Barcellini, Pierre Loap, Kazutoshi Murata, Riccardo Villa, Youlia Kirova, Noriyuki Okonogi, Ester Orlandi
Publié 2021

PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis

par Wasyluk W, Zwolak A
Publié 2021